The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.
Vazquez-Martin
A
A
Oliveras-Ferraros
C
C
del Barco
S
S
Martin-Castillo
B
B
Menendez
J A
JA
D000263:Adenylate Kinase / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000517:prevention & control*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004789:Enzyme Activation; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
D000263:Adenylate Kinase; D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D008687:Metformin; D018719:Erb-b2 Receptor Tyrosine Kinases